Skip to content
GLP1-US
Prices checked Wegovy pill $149 Wegovy pen $349 Zepbound $299–449 Foundayo from $149 Ozempic $349 Medicare Bridge $50 Compounded sema $175 All prices →

FDA labels checked Oct 2026

Wegovy for Teens: Which GLP-1 Drugs Are Approved Under 18

Two GLP-1 drugs are FDA-approved for weight management from age 12: Wegovy injection (since Dec 23, 2022) and Saxenda (since Dec 4, 2020). Zepbound, Foundayo and the Wegovy pill are approved for adults only.

  • Wegovy pen: 12+
  • Saxenda: 12+
  • Zepbound: not approved under 18
  • Foundayo: not approved under 18

We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure

By GLP1-US Editorial TeamUpdated

01 FDA status

GLP-1 Approval Status for Teens, Drug by Drug

DrugUnder 18Details
Wegovy injection Approved 12+ Weight management with obesity (BMI at or above the 95th percentile). Since Dec 23, 2022.
Saxenda (liraglutide 3 mg) Approved 12+ Obesity and body weight over 60 kg (132 lb). Since Dec 4, 2020. Brand ends late Jan 2027.
Zepbound Adults only Label: safety and effectiveness not established in pediatric patients. Teen trials under way.
Foundayo Adults only Pediatric studies deferred by the FDA; a 12 to 17 trial is ongoing.
Wegovy pill, Wegovy HD Adults only The tablet and the 7.2 mg dose are approved for adults.
Mounjaro, Victoza, Trulicity Diabetes only, 10+ Approved for type 2 diabetes from age 10, not for weight loss.

Sources: section 1 and 8.4 of each label; Foundayo approval letter; Drugs@FDA dates. Using Zepbound or Foundayo under 18 would be off-label. The non-GLP-1 pill Qsymia is also approved from age 12 (June 27, 2022).

02 Wegovy

Wegovy for Teens: Who Qualifies and the Dose

The label covers "pediatric patients aged 12 years and older with obesity." For children, obesity means a BMI at or above the 95th percentile for age and sex on the CDC growth charts, not the adult cutoff of 30. There is no "overweight plus a condition" route for teens.

Approved
Dec 23, 2022

ages 12 to 17

Start
0.25 mg/week

same 16-week climb as adults

Maintenance
2.4 mg/week

or 1.7 mg if not tolerated

Not for teens
Pill, HD 7.2 mg

adults only

In STEP TEENS, 87% of teens who finished were on 2.4 mg at the end, and 10% in each group stopped the study drug. Side effects were mostly stomach-related, as in adults. The label's warnings and the thyroid C-cell boxed warning apply at every age. Dosing table: Wegovy dosage; side effects: Wegovy side effects.

03 Saxenda

Saxenda for Teens and Why It Is Ending

Saxenda (liraglutide 3 mg, a daily shot) is approved from age 12 for teens with obesity who weigh more than 60 kg. In its 56-week teen trial of 251 patients, BMI fell 4.3% versus a 0.4% rise on placebo, and 43% versus 19% cut BMI by at least 5%. That is a smaller effect than Wegovy's, from a separate trial.

Ending Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027. Generic liraglutide 3 mg exists, but some versions are also listed as to be discontinued; ask the pharmacist which label the product carries. Details: Saxenda price and discontinuation.

04 Zepbound and Foundayo

Zepbound and Foundayo for Teens: Not Yet

Not FDA-approved for this use

Zepbound (tirzepatide)

The August 2026 label says safety and effectiveness "have not been established in pediatric patients." Lilly's SURMOUNT-ADOLESCENTS trials are testing it in ages 12 to 17; no teen weight indication exists yet. Mounjaro, the same molecule, was approved for type 2 diabetes from age 10 on Dec 19, 2025.

Not FDA-approved for this use

Foundayo (orforglipron)

Approved April 1, 2026 for adults. The FDA's approval letter defers pediatric studies: a 72-week trial in ages 12 to 17 (ATTAIN-ADOLESCENTS) is ongoing, with completion due March 2028, and an 84-week trial in ages 6 to 11 is planned.

05 Guidelines

What Pediatricians Recommend

The American Academy of Pediatrics' 2023 clinical practice guideline says pediatricians should offer adolescents 12 and older with obesity weight-loss medication, as an addition to health behavior and lifestyle treatment, after weighing benefits and risks with the family. Questions families usually raise with the doctor:

  • 1

    How long? Weight tends to return after stopping; treatment is planned as long term.

  • 2

    Eating and growth. Appetite drops a lot, so meals still need enough protein and calories for growth. Raise any history of disordered eating first.

  • 3

    Who prescribes. Usually a pediatrician or a pediatric weight clinic. Many online GLP-1 programs enroll adults only, so check age rules before signing up.

06 Coverage and cost

Insurance and Cost of Wegovy for Teens

Coverage follows the plan's weight-loss benefit. If the employer plan excludes weight-loss drugs, the exclusion usually applies to dependents too. Where it is covered, expect prior authorization with BMI percentile and growth chart notes. Medicaid rules differ by state: see does Medicaid cover weight loss shots. Plan pages: UnitedHealthcare, Aetna, Blue Cross.

Wegovy pen, NovoCare
$349/mo

$199 first 2 fills

List price
$1,349.02

per 4-pen box

Saxenda, Costco
$1,349.20

5 pens, about a month

Sources: NovoCare (Oct 16, 2026), Costco (Oct 17, 2026). NovoCare does not say whether self-pay or the savings card applies to patients under 18; ask NovoCare before you fill. More: Wegovy cost.

For parents 18 and older looking at their own options: PlushCare is insurance-based primary care by video, $19.99 a month membership, $129 a visit without insurance (Oct 2026).

Adults: talk to a PlushCare doctor

07 FAQ

GLP-1 for Teens FAQ

Can teenagers take Wegovy?
Yes. Since December 23, 2022, Wegovy injection is FDA-approved for weight management in children 12 and older with obesity, defined as a BMI at or above the 95th percentile for age and sex. The dose climbs over 16 weeks to 2.4 mg weekly, or 1.7 mg if 2.4 mg is not tolerated. The Wegovy pill is adults only.
Is Zepbound approved for teens?
No. As of October 2026, the Zepbound label says its safety and effectiveness have not been established in pediatric patients. Lilly is running trials in adolescents with obesity. Mounjaro, the same drug, is approved from age 10 but only for type 2 diabetes.
How much weight do teens lose on Wegovy?
In the 68-week STEP TEENS trial of 201 adolescents, BMI fell 16.1% on Wegovy and rose 0.6% on placebo. Body weight fell 14.7% versus a 2.7% gain, and 77% of teens on Wegovy cut BMI by at least 5%, versus 20% on placebo.
Is Foundayo approved for teenagers?
No. Foundayo was approved on April 1, 2026 for adults only. The FDA deferred pediatric studies and requires them after approval, including an ongoing trial in ages 12 to 17 and a planned one in ages 6 to 11.
What do pediatricians recommend?
The American Academy of Pediatrics 2023 guideline says pediatricians should offer adolescents 12 and older with obesity weight-loss medication as an addition to health behavior and lifestyle treatment, based on benefits, risks and the family's goals. Medication is not meant to replace lifestyle care.
Does insurance cover Wegovy for teens?
It depends on the plan. Commercial plans that cover weight-loss drugs may cover Wegovy for teens with prior authorization; many employer plans exclude weight-loss drugs at any age. Medicaid rules vary by state. Ask the plan about Wegovy for a patient aged 12 to 17 by name.

Related: what GLP-1 is used for · FDA approvals timeline · BMI calculator.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.

Checked against primary sources such as FDA labels, CMS and provider pages
Updated
How we check facts →